Does the media prefer VNDA or ZBIO?

In the previous week, Zenas BioPharma had 2 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 5 mentions for Zenas BioPharma and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.73 beat Zenas BioPharma's score of 0.64 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VNDA or MNKD?

In the previous week, MannKind had 14 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 17 mentions for MannKind and 3 mentions for Vanda Pharmaceuticals. MannKind's average media sentiment score of 0.73 beat Vanda Pharmaceuticals' score of 0.73 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VNDA or LXRX?

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 3 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 0.73 beat Lexicon Pharmaceuticals' score of 0.47 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VNDA or OPK?

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 3 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 0.73 beat OPKO Health's score of 0.72 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VNDA or GERN?

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 3 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 0.73 beat Geron's score of 0.65 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vanda Pharmaceuticals (VNDA) Competitors

$6.09 -0.04 (-0.65%)

Closing price 04:00 PM Eastern

Extended Trading

$6.08 -0.01 (-0.16%)

As of 07:28 PM Eastern

Compare

VNDA vs. ZBIO, MNKD, LXRX, OPK, and GERN

Should you buy Vanda Pharmaceuticals stock or one of its competitors? MarketBeat compares Vanda Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vanda Pharmaceuticals include Zenas BioPharma (ZBIO), MannKind (MNKD), Lexicon Pharmaceuticals (LXRX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry.

How does Vanda Pharmaceuticals compare to Zenas BioPharma?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

In the previous week, Zenas BioPharma had 2 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 5 mentions for Zenas BioPharma and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.73 beat Zenas BioPharma's score of 0.64 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vanda Pharmaceuticals currently has a consensus target price of $14.30, indicating a potential upside of 134.81%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 154.52%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vanda Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, meaning that its stock price is 171% less volatile than the broader market.

Zenas BioPharma has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -109.99%. Vanda Pharmaceuticals' return on equity of -32.26% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
Zenas BioPharma	N/A	-99.99%	-58.06%

Vanda Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.69	-$220.47M	-$4.05	N/A
Zenas BioPharma	$10M	109.85	-$377.74M	-$8.47	N/A

Summary

Vanda Pharmaceuticals beats Zenas BioPharma on 9 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to MannKind?

Vanda Pharmaceuticals (NASDAQ:VNDA) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

MannKind has a net margin of -6.63% compared to Vanda Pharmaceuticals' net margin of -109.99%. MannKind's return on equity of -11.21% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
MannKind	-6.63%	-11.21%	-3.92%

In the previous week, MannKind had 14 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 17 mentions for MannKind and 3 mentions for Vanda Pharmaceuticals. MannKind's average media sentiment score of 0.73 beat Vanda Pharmaceuticals' score of 0.73 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MannKind has higher revenue and earnings than Vanda Pharmaceuticals. MannKind is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.69	-$220.47M	-$4.05	N/A
MannKind	$348.97M	2.97	$5.86M	-$0.07	N/A

Vanda Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, MannKind has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Vanda Pharmaceuticals currently has a consensus target price of $14.30, suggesting a potential upside of 134.81%. MannKind has a consensus target price of $8.97, suggesting a potential upside of 166.93%. Given MannKind's stronger consensus rating and higher probable upside, analysts plainly believe MannKind is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

MannKind beats Vanda Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Vanda Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Vanda Pharmaceuticals presently has a consensus price target of $14.30, suggesting a potential upside of 134.81%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 145.95%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Vanda Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.69	-$220.47M	-$4.05	N/A
Lexicon Pharmaceuticals	$49.80M	16.50	-$50.34M	-$0.07	N/A

Lexicon Pharmaceuticals has a net margin of -37.46% compared to Vanda Pharmaceuticals' net margin of -109.99%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 3 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 0.73 beat Lexicon Pharmaceuticals' score of 0.47 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lexicon Pharmaceuticals beats Vanda Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to OPKO Health?

Vanda Pharmaceuticals (NASDAQ:VNDA) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Vanda Pharmaceuticals has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.69	-$220.47M	-$4.05	N/A
OPKO Health	$606.90M	1.82	-$225.68M	-$0.27	N/A

Vanda Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Vanda Pharmaceuticals currently has a consensus target price of $14.30, suggesting a potential upside of 134.81%. OPKO Health has a consensus target price of $1.55, suggesting a potential upside of 6.16%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vanda Pharmaceuticals is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 49.7% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

OPKO Health has a net margin of -36.63% compared to Vanda Pharmaceuticals' net margin of -109.99%. OPKO Health's return on equity of -16.78% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
OPKO Health	-36.63%	-16.78%	-10.98%

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 3 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 0.73 beat OPKO Health's score of 0.72 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

OPKO Health beats Vanda Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Geron?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Vanda Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Geron has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Vanda Pharmaceuticals presently has a consensus target price of $14.30, suggesting a potential upside of 134.81%. Geron has a consensus target price of $2.50, suggesting a potential upside of 115.52%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Vanda Pharmaceuticals is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Geron has lower revenue, but higher earnings than Vanda Pharmaceuticals. Geron is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.69	-$220.47M	-$4.05	N/A
Geron	$183.88M	4.05	-$83.50M	-$0.11	N/A

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Geron has a net margin of -35.48% compared to Vanda Pharmaceuticals' net margin of -109.99%. Geron's return on equity of -23.31% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
Geron	-35.48%	-23.31%	-10.08%

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 3 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 0.73 beat Geron's score of 0.65 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vanda Pharmaceuticals beats Geron on 9 of the 15 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VNDA vs. The Competition

Export

Metric	Vanda Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$368.63M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-1.50	9.91	18.89	22.53
Price / Sales	1.69	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	1.10	6.63	9.84	6.72
Net Income	-$220.47M	$24.20M	$3.57B	$337.19M
7 Day Performance	-5.73%	-3.24%	-1.16%	0.48%
1 Month Performance	-13.00%	0.53%	3.85%	5.07%
1 Year Performance	38.72%	47.24%	27.40%	34.25%

Vanda Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VNDA Vanda Pharmaceuticals	2.3135 of 5 stars	$6.09 -0.7%	$14.30 +134.8%	+42.6%	$368.63M	$216.10M	N/A	290
ZBIO Zenas BioPharma	3.6279 of 5 stars	$18.97 flat	$44.29 +133.5%	+70.3%	$1.20B	$10M	N/A	N/A	Analyst Forecast
MNKD MannKind	4.2353 of 5 stars	$3.38 flat	$8.84 +161.6%	-20.0%	$1.04B	$348.97M	N/A	400	Analyst Forecast
LXRX Lexicon Pharmaceuticals	1.9471 of 5 stars	$2.16 flat	$4.55 +110.6%	+204.1%	$959.46M	$69.64M	N/A	140	Gap Up
OPK OPKO Health	1.7196 of 5 stars	$1.27 flat	$1.55 +22.0%	+1.4%	$958.96M	$606.90M	N/A	1,373

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VNDA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. ZBIO, MNKD, LXRX, OPK, and GERN

How does Vanda Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Vanda Pharmaceuticals compare to MannKind?

Summary

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Summary

How does Vanda Pharmaceuticals compare to OPKO Health?

Summary

How does Vanda Pharmaceuticals compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. ZBIO, MNKD, LXRX, OPK, and GERN

How does Vanda Pharmaceuticals compare to Zenas BioPharma?

Does the media prefer VNDA or ZBIO?

Do analysts recommend VNDA or ZBIO?

Do institutionals & insiders have more ownership in VNDA or ZBIO?

Which has more volatility & risk, VNDA or ZBIO?

Is VNDA or ZBIO more profitable?

Which has better valuation & earnings, VNDA or ZBIO?

Summary

How does Vanda Pharmaceuticals compare to MannKind?

Is VNDA or MNKD more profitable?

Does the media prefer VNDA or MNKD?

Do insiders and institutionals believe in VNDA or MNKD?

Which has preferable valuation & earnings, VNDA or MNKD?

Which has more risk & volatility, VNDA or MNKD?

Do analysts recommend VNDA or MNKD?

Summary

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Which has more volatility and risk, VNDA or LXRX?

Do analysts prefer VNDA or LXRX?

Which has preferable earnings & valuation, VNDA or LXRX?

Is VNDA or LXRX more profitable?

Do insiders & institutionals believe in VNDA or LXRX?

Does the media prefer VNDA or LXRX?

Summary

How does Vanda Pharmaceuticals compare to OPKO Health?

Which has stronger valuation & earnings, VNDA or OPK?

Which has more risk & volatility, VNDA or OPK?

Do analysts rate VNDA or OPK?

Do institutionals and insiders believe in VNDA or OPK?

Is VNDA or OPK more profitable?

Does the media prefer VNDA or OPK?

Summary

How does Vanda Pharmaceuticals compare to Geron?

Which has more risk & volatility, VNDA or GERN?

Do analysts rate VNDA or GERN?

Which has better valuation and earnings, VNDA or GERN?

Do institutionals and insiders hold more shares of VNDA or GERN?

Is VNDA or GERN more profitable?

Does the media refer more to VNDA or GERN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools